Do men have biological clocks as new autism finding suggests?

By Deborah Kotz, Globe Staff

After reading news reports linking a babys risk of having autism with the fathers -- not mothers -- biological age, Im guessing women felt a little vindicated; finally, researchers have acknowledged that were not the only ones with a biological clock thats ticking away.

The study, published Wednesday in the journal Nature, found that the number of DNA changes or mutations increase with age making it more likely for older fathers to pass along mutations involved in autism or schizophrenia. While a young 25-year-old father passes along an average of 25 new mutations to his child via his sperm, a 40-year-old transmits 65 mutations. Moms, on the other hand, transmit an average of 15 new mutations regardless of their age, the Icelandic researchers found.

And the solution seems so simple: Collecting the sperm of young adult men and cold-storing it for later use could be a wise individual decision, Alexey Kondrashov, a professor of evolutionary biology at the University of Michigan in Ann Arbor, wrote in an editorial that accompanied the study.

So, are moms really off the hook when it comes to determining autism risk, and should young men really think about banking their sperm just as women have been told to consider egg freezing to preserve their fertility?

Banking sperm doesnt sound like the worst idea, said Dr. Martha Herbert, a pediatric neurologist at Massachusetts General Hospital and author of The Autism Revolution. But theres also no reason to panic since these types of mutations probably play a minority role in the development of autism.

Age certainly can increase genetic mutations, but so can a variety of lifestyle factors including smoking and having a poor diet thats lacking in nutrient dense foods like fresh fruits and vegetables, fish, and whole grains. A diet high in sugar, fast food, and packaged goods increases harmful inflammation, said Herbert. This same process thats thought to be involved in obesity, she added, also can damage a cells DNA.

Previous research has shown that any sort of stress on the body -- from a strenuous job to lack of sleep -- can also increase genetic damage, and they, too, could play a role in determining autism risk.

Intense exercise might be another good thing to avoid, said Herbert, since it can overtax the body leading to DNA damage that might also increase autism risk in babies conceived by strenuous fitness buffs. Men, in particular, have been drawn to extreme workout videos and boot-camp classes that extol the benefits of getting the heart to pump at or near its maximum rate for an extended period of time.

Researchers are starting to explore whether this extreme form of exercise causes more harm than benefits, according to Herbert, especially following the sudden death in May of 58-year-old ultramarathon runner Micah True from heart failure.

View post:
Do men have biological clocks as new autism finding suggests?

Study: Father’s age a likely factor in autism

(CBS News) The cause of autism is one of the great mysteries of medicine, but we found out something new and important Wednesday.

A report in the medical journal "Nature" says it is the age of the father at the time of conception, not the age of the mother that can raise the risk of autism in a child.

With more men becoming fathers later in life, it could help explain the rise in autism.

The study's senior author - a scientist in Iceland - writes: "Conventional wisdom has been to blame the developmental disorders of children on the age of mothers"... but "it is the age of fathers that appears to be the real culprit."

Dr. Delores Maldespina, a psychiatrist at New York University, said she finds the research eye opening.

"This study shows that new mutations are frequent enough as men age that fathers aging alone can explain the increase for the risk of autism," Maldespina said.

The study says a father's age could account for 15 to 30 percent of cases of autism, and perhaps other disorders like schizophrenia as well.

"This study shows that when these diseases present without a family history, the origin is in the sperm of the man and that the risk goes up as the man ages," Maldespina said.

The latest numbers from the Centers for Disease Control indicate the rate of autism has doubled in the last six years from 1 in 162, to 1 in 88.

The number of men 40 and older who father a child has increased by more than 30 percent since 1980. The study is the first to quantify the consequence of a father's age: For every 1-year of age, two genetic mutations were discovered in offspring that could be traced to the father, and up to 65 mutations in the offspring of 40-year-old men. The average number of mutations traced to the mother was 15, no matter what her age.

Read the original post:
Study: Father's age a likely factor in autism

Study: Father's age a likely factor in autism

(CBS News) The cause of autism is one of the great mysteries of medicine, but we found out something new and important Wednesday.

A report in the medical journal "Nature" says it is the age of the father at the time of conception, not the age of the mother that can raise the risk of autism in a child.

With more men becoming fathers later in life, it could help explain the rise in autism.

The study's senior author - a scientist in Iceland - writes: "Conventional wisdom has been to blame the developmental disorders of children on the age of mothers"... but "it is the age of fathers that appears to be the real culprit."

Dr. Delores Maldespina, a psychiatrist at New York University, said she finds the research eye opening.

"This study shows that new mutations are frequent enough as men age that fathers aging alone can explain the increase for the risk of autism," Maldespina said.

The study says a father's age could account for 15 to 30 percent of cases of autism, and perhaps other disorders like schizophrenia as well.

"This study shows that when these diseases present without a family history, the origin is in the sperm of the man and that the risk goes up as the man ages," Maldespina said.

The latest numbers from the Centers for Disease Control indicate the rate of autism has doubled in the last six years from 1 in 162, to 1 in 88.

The number of men 40 and older who father a child has increased by more than 30 percent since 1980. The study is the first to quantify the consequence of a father's age: For every 1-year of age, two genetic mutations were discovered in offspring that could be traced to the father, and up to 65 mutations in the offspring of 40-year-old men. The average number of mutations traced to the mother was 15, no matter what her age.

Read the original post:
Study: Father's age a likely factor in autism

Controversial auditory therapy may be beneficial for kids with autism

Any parent or teacher of a child with autism will tell you the heartbreak they feel when they call a child's name and he or she doesn't respond. This most basic social interaction is often a challenge for children on the autism spectrum and in turn, more complex social exchanges seem insurmountable.

"I'm less worried about his academic skills. I want him to be able to be in a room with people and like being there," said one parent of a child with autism that I know. "I want people to like having him there."

Related: Doctors announce FDA-approved trial to cure autism with cord blood

This desire for engagement is common for families raising children with autism, whose social and attention deficits often account for a significant amount of their challenges.

Parents have been seeking therapies to increase attention and interaction for years. One treatment continues to remain a part of the conversation today.

Auditory integration training, or AIT, was developed in the 1950s by Dr. Guy Berard, an otolaryngologist, in Annecy, France. Originally designed to improve hearing loss or other hearing impairments, Berard considered hearing imbalances and poor auditory processing skills a contributing factor to academic, social, and behavioral challenges such as learning disabilities, autism and attention deficit disorder. He felt the disorders could be improved using AIT.

Other models of AIT exist, but the Berard method remains the most popular. Berard developed the AudioKinetron and the Earducator, devices that deliver music at specific frequencies through headphones. The regimen includes two, 30-minute sessions, three hours apart each day over the course of 10 days. A one- or two-day break may be taken after the first five days. Candidates must be at least 3 years of age and may have a diagnosis of autism, pervasive developmental disorder (PDD), ADHD, central auditory processing disorder, or other learning disabilities or processing disorders.

Audio tests are administered before, during and after the treatment to monitor and assess progress and make necessary adjustments as needed.

The goal of AIT in individuals with autism is to improve auditory distortions, delays or sensitivities. The theory is if processing functions better, an individual will be able to sustain increased attention, which in turn allows greater opportunity for awareness, comprehension and engagement.

Like many treatments for autism, there are both supporters and critics of AIT. A 1994 study by Bernard Rimland and Stephen Edelson assessed the affect of AIT on 445 adults and children with autism. Though the researchers noted no difference in the results of auditory tests between subjects, many parents reported a decrease in problem behaviors after AIT intervention.

See the article here:
Controversial auditory therapy may be beneficial for kids with autism

Father’s Age Linked to Autism

Latest Mental Health News

Risk of Genetic Mutations Tied to Autism May Increase With Each Year of Father's Age

By Jennifer Warner WebMD Health News

Reviewed by Louise Chang, MD

Aug. 22, 2012 -- The father's age may matter more than the mother's when it comes to the risk of some disorders like autism in children.

A new study shows the number of "de novo" or new genetic mutations passed to children increases with every year of the father's age at the time of conception. And fathers pass along a greater number of these to their children than do mothers.

Researchers found the number of de novo mutations in children increases by two for every year of the father's age. The whole amount doubles every 16.5 years.

That means a 36-year-old man passes along twice as many mutations in his sperm to his children, compared to a 20-year-old.

Previous studies have already linked these mutations to autism and schizophrenia and a variety of other developmental disorders. This study helps to quantify the potential risk.

Researchers say the findings have important implications for family planning as well as the recent rise of developmental disorders, especially autism.

See the article here:
Father's Age Linked to Autism

Father's Age Linked to Autism

Latest Mental Health News

Risk of Genetic Mutations Tied to Autism May Increase With Each Year of Father's Age

By Jennifer Warner WebMD Health News

Reviewed by Louise Chang, MD

Aug. 22, 2012 -- The father's age may matter more than the mother's when it comes to the risk of some disorders like autism in children.

A new study shows the number of "de novo" or new genetic mutations passed to children increases with every year of the father's age at the time of conception. And fathers pass along a greater number of these to their children than do mothers.

Researchers found the number of de novo mutations in children increases by two for every year of the father's age. The whole amount doubles every 16.5 years.

That means a 36-year-old man passes along twice as many mutations in his sperm to his children, compared to a 20-year-old.

Previous studies have already linked these mutations to autism and schizophrenia and a variety of other developmental disorders. This study helps to quantify the potential risk.

Researchers say the findings have important implications for family planning as well as the recent rise of developmental disorders, especially autism.

See the article here:
Father's Age Linked to Autism

TiGenix : Business Update & Financial Highlights for the First Half of 2012

Regulated information August 23, 2012

TiGenix Business Update & Financial Highlights for the First Half of 2012

Leuven (BELGIUM) - August 23, 2012 -TiGenix NV (NYSE Euronext: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the half year ending June 30, 2012.

Business highlights

Financial highlights

"The significant progress in all our clinical programs and the commercial ramp up of ChondroCelect in the first half year of 2012 reinforce our position as the European leader in cell therapy," says Eduardo Bravo, CEO of TiGenix. "We continue to consistently deliver on the objectives we set more than a year ago, keeping all key programs on plan, meeting our aggressive targets, and keeping costs under control. In addition, we are in discussions with a number of companies in connection with the US rights to Cx601."

Business update

Commercial roll-out of ChondroCelect continues to gain momentum

ChondroCelect sales for the first half of 2012 amounted to EUR 2.1 million, comprising EUR 1.5 million from 2012 sales, up 115% compared to the same period of last year, and EUR 0.7 million of deferred sales from 2011 as a result of the retroactive reimbursement in the Netherland per January 1, 2011.

Discussions to obtain full national reimbursement keep advancing in Spain, France, and Germany. In addition to the recent important reimbursement success, the Company has obtained a positive decision in the Netherlands by one of the leading private healthcare insurance companies to make treatment with ChondroCelect compulsory for its insured, no longer reimbursing non-ATMP cartilage products. Similarly, two of the large private insurers in the UK expressed their intention to routinely reimburse ChondroCelect going forward.

Go here to see the original:
TiGenix : Business Update & Financial Highlights for the First Half of 2012

TiGenix : Business Update & Financial Highlights for the First Half of 2012

Regulated information August 23, 2012

TiGenix Business Update & Financial Highlights for the First Half of 2012

Leuven (BELGIUM) - August 23, 2012 -TiGenix NV (NYSE Euronext: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the half year ending June 30, 2012.

Business highlights

Financial highlights

"The significant progress in all our clinical programs and the commercial ramp up of ChondroCelect in the first half year of 2012 reinforce our position as the European leader in cell therapy," says Eduardo Bravo, CEO of TiGenix. "We continue to consistently deliver on the objectives we set more than a year ago, keeping all key programs on plan, meeting our aggressive targets, and keeping costs under control. In addition, we are in discussions with a number of companies in connection with the US rights to Cx601."

Business update

Commercial roll-out of ChondroCelect continues to gain momentum

ChondroCelect sales for the first half of 2012 amounted to EUR 2.1 million, comprising EUR 1.5 million from 2012 sales, up 115% compared to the same period of last year, and EUR 0.7 million of deferred sales from 2011 as a result of the retroactive reimbursement in the Netherland per January 1, 2011.

Discussions to obtain full national reimbursement keep advancing in Spain, France, and Germany. In addition to the recent important reimbursement success, the Company has obtained a positive decision in the Netherlands by one of the leading private healthcare insurance companies to make treatment with ChondroCelect compulsory for its insured, no longer reimbursing non-ATMP cartilage products. Similarly, two of the large private insurers in the UK expressed their intention to routinely reimburse ChondroCelect going forward.

Go here to see the original:
TiGenix : Business Update & Financial Highlights for the First Half of 2012

Autism And Cord Blood Stem Cells: FDA Gives Green Light For Groundbreaking Clinical Trial

Sacramento, CA /PRNewswire/ Sutter Neuroscience Institute, a recognized Center of Excellence, andCBR(Cord Blood Registry), the worlds largest stem cell bank, are launching the firstFDA- approved clinical trial to assess the use of a childs own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.

According to the Centers for Disease Control and Prevention, autism spectrum disorders impact one in 88 children in the U.S., and one in 54 boys.1The condition is thought to have multiple risk factors including genetic, environmental and immunological components.

This is the start of a new age of research in stem cell therapies for chronic diseases such as autism, and a natural step to determine whether patients receive some benefit from an infusion of their own cord blood stem cells, said Michael Chez, M.D., director of Pediatric Neurology with the Sutter Neuroscience and principal study investigator. I will focus on a select portion of children diagnosed with autism who have no obvious cause for the condition, such as known genetic syndromes or brain injury.

The study will enroll 30 children between the ages of two and seven, with a diagnosis of autism who meet theinclusion criteria for the study. Enrolled participants will receive two infusionsone of the childs own cord blood stem cells and one of a placeboover the course of 13 months. Both the participants and the lead investigators will be blinded from knowing the content of each infusion. To ensure the highest quality and consistency in cord blood stem cell processing, storage and release for infusion,CBRis the only family stem cell bank providing units from clients for the study.

For information on study, visithttp://www.cordblood.com/autism.

Study Rationale A newborns umbilical cord blood contains a unique population of stem cells that have been used for more than 20 years in medical practice to treat certain cancers, blood diseases and immune disorders. When patients undergo a stem cell transplant for these conditions, the stem cells effectively rebuild the blood and immune systems.

A focus of my research has been the complex relationship between a childs immune system and central nervous system. We have evidence to suggest that certain children with autism have dysfunctional immune systems that may be damaging or delaying the development of the nervous system, continued Dr. Chez. Cord blood stem cells may offer ways to modulate or repair the immune systems of these patients which would also improve language and some behavior in children who have no obvious reason to have become autistic. The study is similar to otherFDA-approved clinical trials looking at cord blood stem cells as a therapy for cerebral palsy.

Its exciting to partner with thought-leading medical researchers and clinicians, like Dr. Chez, who are pursuing a scientifically-sound approach in evaluating new therapeutic uses for cord blood stem cells for conditions that currently have no cures, said Heather Brown, vice president of scientific & medical affairs atCBR. Families who made the decision to bank their stem cells to cover the unknowns and what ifs in life are gaining access to this and other important clinical trials while playing an important role in the advancement of science.

The co-investigator of the study is Michael Carroll, M.D., medical director of the Blood and Marrow Transplantation and Hematological Malignancies Program at Sutter Medical Center, Sacramento.

There is a vast amount of unchartered territory when it comes to how stem cell therapies may help patients living with these conditions, said Dr. Carroll. Ive seen how stem cell therapy has changed my field of medicine and how I care for my blood cancer patients. I am eager to see how our work can open new doors for patients and families dealing with autism.

Excerpt from:
Autism And Cord Blood Stem Cells: FDA Gives Green Light For Groundbreaking Clinical Trial

New Partnership to Drive Mass Production of Life-Saving Stem Cells

TORONTO, ONTARIO--(Marketwire -08/23/12)- Stem cells hold great promise for treating and curing numerous diseases; however, a major challenge facing scientists is how to produce stem cells in the massive quantities required for clinical use. The McEwen Centre for Regenerative Medicine (McEwen Centre) and the Centre for Commercialization of Regenerative Medicine (CCRM) are partnering to establish a fund that will drive research in this area.

The McEwen Centre-CCRM Commercialization Impact Prize launches today, and will solicit innovative ideas from regenerative medicine scientists working in labs throughout the McEwen Centre. The winning team(s) will be awarded up to $600,000 to pursue research that will determine how to manufacture stem cells for clinical use and drug screening.

"This private-public funding partnership is an important step forward to accelerating the advance of a discovery from a lab bench to the patient and onto the global market. Scientists at the McEwen Centre are making significant progress towards finding a cure for diseases such as Type 1 diabetes and heart disease. Collaborative partnerships are the key to discovering the cures sooner!" says Rob McEwen, co-founder of the McEwen Centre, and Chief Owner, McEwen Mining.

Deadline for submissions is October 15, 2012. The Prize will fund up to two, 2-year projects that address the following challenges:

"Overcoming the scale-up and manufacturing challenge of stem cells would be a huge advancement for the regenerative medicine (RM) industry and this initiative fits in perfectly with our mandate to bridge the RM commercialization gap," explains Dr. Michael May, CEO of the Centre for Commercialization of Regenerative Medicine. "We're very pleased to be working with the McEwen Centre, already a partner of ours, to make this happen."

The Commercialization Impact Prize budget template and application form can be found here: http://ccrm.ca/Commercialization-Impact-Prize or http://mcewencentre.com/ccrm.

About McEwen Centre for Regenerative Medicine

The McEwen Centre for Regenerative Medicine was founded by Rob and Cheryl McEwen in 2003 and opened its doors in 2006. The McEwen Centre for Regenerative Medicine, part of Toronto-based University Health Network, is a world leading centre for stem cell research, facilitating collaboration between renowned scientists from 5 major hospitals in Toronto, the University of Toronto and around the world. Supported by philanthropic contributions and research grants, McEwen Centre scientists strive to introduce novel regenerative therapies for debilitating and life threatening illnesses including heart disease, spinal cord injury, diabetes, diseases of the blood, liver and arthritis.

About Centre for Commercialization of Regenerative Medicine (CCRM)

CCRM, a Canadian not-for-profit organization funded by the Government of Canada's Networks of Centres of Excellence program and six institutional partners, supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. A network of academics, industry and entrepreneurs, CCRM translates scientific discoveries into marketable products for patients. CCRM launched in Toronto's Discovery District on June 14, 2011.

Originally posted here:
New Partnership to Drive Mass Production of Life-Saving Stem Cells

Repairing cartilage with fat: Problems and potential solutions

Public release date: 23-Aug-2012 [ | E-mail | Share ]

Contact: Hilary Glover hilary.glover@biomedcentral.com 44-020-319-22370 BioMed Central

Stem cells isolated from fat are being considered as an option for treating tissue damage and diseases because of their accessibility and lack of rejection. New research published in BioMed Central's open access journal Stem Cell Research & Therapy shows that this is not as straightforward as previously believed, and that fat-derived stem cells secrete VEGF and other factors, which can inhibit cartilage regeneration. However pre-treating the cells with antibodies against VEGF and growing them in nutrients specifically designed to promote chondrocytes can neutralize these effects.

Chondrocytes make and maintain healthy cartilage but damage and disease including osteoarthritis can destroy cartilage resulting in pain and lack of mobility. Stem cell therapy using cells isolated from adult tissue (such as fat) are being investigated as a way of repairing this damage. Stem cells have the ability to become many different types of tissue so the real trick is persuading them to become cartilage rather than bone, or blood vessels, for example.

Researchers from the Georgia Institute of Technology found that adipose (fat) stem cells (ASCs) secrete large amounts of factors, especially the growth factor VEGF, which prevent cartilage regeneration and actually causes the death (apoptosis) of chondrocytes along with the formation of blood vessels. Treating ASCs with medium designed to encourage their differentiation into cartilage cells was able to reduce the amount of these secreted factors and also prevented the growth of blood vessels. Specifically, an antibody designed to neutralize VEGF prevented chondrocyte apoptosis.

Prof Barbara Boyan, who led this research, explained, "Non-treated ASCs actually impeded healing of hyaline cartilage defects, and although treating ASCs improved the situation they added no benefit to compared to cartilage allowed to heal on its own. However we only looked at cartilage repair for a week after treatment, and other people have shown that two to six weeks is required before the positive effect of ASCs on influence cartilage regeneration is seen."

So while stem cells from fat may be able to help repair damaged cartilage, careful handling and pre-treatment may be required to ensure a positive result.

###

Media contact

Dr Hilary Glover Scientific Press Officer, BioMed Central Tel: +44 (0) 20 3192 2370 Mob: +44 (0) 778 698 1967 Email: hilary.glover@biomedcentral.com

Read the rest here:
Repairing cartilage with fat: Problems and potential solutions

Nanofibres 'may pose health risk'

23 August 2012 Last updated at 22:27 ET

Inhaling tiny fibres made by the nanotechnology industry could cause similar health problems to asbestos, say researchers.

Some are similar in shape to asbestos fibres, which have caused lung cancers such as mesothelioma.

Research on mice, published in Toxicology Sciences, suggests the longer nanofibres are more dangerous.

Human and mouse lungs are different, but the researchers hope the study will help to design safer nanofibres.

Nanofibres are in a range of goods, from airplane wings to tennis rackets.

Ken Donaldson, professor of respiratory toxicology at the University of Edinburgh, said: "Concern has been expressed that new kinds of nanofibres being made by nanotechnology industries might pose a risk because they have a similar shape to asbestos."

Silver nanofibres of varying lengths were injected into the lungs of mice.

Those larger than five micrometres, or five-thousandths of a millimetre, tended to become lodged in the lungs and cause inflammation. The smaller ones were cleared from the lungs.

Prof Donaldson said: "We knew that long fibres, compared with shorter fibres, could cause tumours, but until now we did not know the cut-off length at which this happened.

See the rest here:
Nanofibres 'may pose health risk'

Regents discuss medical school, bonuses for admins

University of Texas System Chancellor Francisco Cigarroa noted progress on the projects slated to directly impact South Texas including a regional medical school and independent UTB at a UT System meeting Thursday.

The UT System Board of Regents heard the first annual report on the plan Cigarroa presented one year ago. The Rio Grande Valley figures significantly in several components of UT Systems extensive undertaking known as A Framework for Advancing Excellence.

The UT System board also approved an incentive plan for university presidents, including University of Texas at Brownsville President Juliet V. Garcia.

The futures of our children and our grandchildren are at stake, Cigarroa wrote in his letter opening the progress report. How do we make higher education more accessible and affordable to an increasing number of students? How do we produce more doctors, nurses and health professionals and improve the quality of health care in Texas?

Part of the answer, Cigarroa wrote, is a team effort that includes not only UT System campuses, but experts and consultants, too.

Incentive plan

How well UTB transitions into an independent university could be a factor in a potential bonus for President Garcia based on the incentive plan the UT regents approved Wednesday. Administration executive officers also fall under the plan.

In 2011, Garcias salary was $304,179, and within that contract she also received a one-time merit award of $32,272.

View post:
Regents discuss medical school, bonuses for admins

NIB 12 WEST: Chemistry is key to Cavaliers equation

Despite a relatively inexperienced squad, sixth-year La Salle-Peru head coach Joe Sassano is hoping a strong team chemistry from his hard-working Cavaliers will carry them through and offset that lack of experience this fall on the gridiron.

The junior-dominated 48-man L-P roster is made up of 19 seniors, 27 juniors and two sophomores.

"They've just got a good work ethic and they've bonded together," said Sassano of his team.

Triggering a "potentially explosive" Cavs offense will be third-year starting quarterback Zack Cinotto, an All-NIB 12 West selection in 2011 after passing for just lass than 1,400 yards as a junior. The strong-armed, 6-foot-1, 210-pound slinger who is on the recruiting radar of college coaches has thrown for more than 2,300 yards during his two varsity seasons.

One of the players who will be responsible for protecting Cinotto and giving him time to fire away will be senior left tackle D.J. Wilmot (6-5, 225) L-P's lone returning lineman.

A couple of expected weapons for Cinotto will be running back Victor Espindola and wide receiver Adam Happ.

"We have the potential to be explosive and hit the big plays," Sassano said. "And I think as the season goes on, we'll be able to, hopefully, control the ball a little bit and be able to move it running. We've got some running backs that can make some things happen.

"Our goal is to be able to have a balanced attack."

The L-P defense welcomes back a trio of starters in linebackers Seth Schiffbauer and Kyle Jenkins, along with safety Billy Vickers. A pair of key players on the Cavaliers D-line will be tackles Michael Denyes (6-3, 220) and Chris Morehouse (6-0, 205).

"Obviously, we're going to have some inexperienced players out there, but yet, they seem to want to play some physical football. I think we've got some tough kids," Sassano said. "And we've got some good speed in our secondary."

View post:
NIB 12 WEST: Chemistry is key to Cavaliers equation

The Chemistry of Love

Take this all with a grain of salt, but a book being published next month by Current/Penguin, The Chemistry Between Us: Love, Sex and the Science of Attraction, argues that all the sexy, impatient, bored, jealous, secure feelings you think you have regarding loveabout your boyfriend or husband, the hot guy in the office, your ex are really neurological responses to the chemical cocktails that flow through your veins. Youre not making decisions or choices, not really. Youre following the requirements of biology, and then telling yourself a culturally acceptable fiction like "love at first sight," or "just my type," or "so glad I dumped that douchebag cheater."

The authors, Larry Young and Brian Alexander, are a neuroscientist and a journalist, respectively. They're particularly interested in the rest of the animal kingdom species that haven't developed stories by which we explain away our biological impulses. By describing experiments in which researchers masturbate female rats, stimulate the cevixes of ewes, and study the cheating behavior of otherwise monogamous voles and zebra finches, they trace the biological foundations of human bonding.

So as an end-of-summer public service, I thought I'd pass along three of Young and Alexander's tips on love and marriage.

1. Dont marry the guy you meet while youre ovulating.

The fertile period womans cycle has demonstrable effects on her appearance and behavior. The timbre of her voice changes. She takes more care with her appearance. She becomes more flirtatious. Men notice: Studies have shown that strippers who are ovulating make more money than those who are not. A University of New Mexico psychologist found that ovulating strippers made $354 per five hour shift, as opposed to $264 for non-ovulating strippers. Menstruating strippers earned even less.

But women also make riskier decisions at the fertile time of the month. Theyre likelier to hook up with a stranger, likelier to respond to the attentions of a bad boy type, likelier to rent a house, sight unseen. Heather Rupp is a neuroscientist whose experiments on ovulating women are chronicled in Chemistry. The guy you are most likely to pick mid-cycle he is not necessarily the guy who is going to raise your children, she says. The perfect guy is the guy you like across the entire cycle, and they are rare!

2. Size matters.

Oxytocin is a hormone that triggers bonding, especially in women and especially between women and their babies. It is released through the stimulation of the cervix (which explains, partly, the bonding that occurs between mother and infant after labor). Scientists at the University of Cambridge found in the eighties that if they stimulated the cervixes of ewes (with a dildo!) who had not recently given birth, the ewes behaved maternally toward lambs that did not belong to them. They exhibited the full complement of maternal behavior after five minutes of vaginal-cervical stimulation, the scientists wrote.

Thus Young believes that the human penis has a similar, evolutionary purpose: To massage his sex partners cervix and thus release in her maternal feelings for him: "Men are using their penises to entice women to babysit them.

3. Some men have a bad boyfriend gene.

Read the original post:
The Chemistry of Love

Grey’s Anatomy Admits Newcomer Tessa Ferrer for Recurring Role

Aug 23, 2012 06:31 PM ET by Kate Stanhope Follow katestanhope Tweet

Tessa Ferrer

Grey's Anatomy may have lost a few faces this past year, but there will be plenty of newbies roaming the halls when the medical drama returns this fall.

Newcomer Tessa Ferrer has scored a recurring role on the ABC drama's upcoming ninth season, TVLine reports.

Exclusive: Veronica Mars alum Tina Majorino lands a Grey's gig

It is unknown whether Ferrer will play a character based at Seattle Grace, or if she'll be tied to one of the new hospitals to be featured on the show this season when several longtime characters start their new gigs.

Grey's marks Ferrer's TV debut, where she joins new recurring guest stars Veronica Mars vet Tina Majorino, Friday Night Lights' Gaius Charles and True Blood's Camilla Luddington. Former series regulars Chyler Leigh and Kim Raver will not returning come fall, and Eric Dane is set to wrap his arc early in Season 9.

The new season of Grey's Anatomy premieres on Thursday, Sept. 27 at 9/8c on ABC.

Read more here:
Grey’s Anatomy Admits Newcomer Tessa Ferrer for Recurring Role

'The Owner’s Cottage' in line for World Travel Award

'The Owners Cottage at the 5-star, award-winning Grande Provence Heritage Wine Estate, Franschhoek, part of Huka Retreats Huka Lodge in New Zealand and Dolphin Island in Fiji has been nominated once again in the category of South Africas Leading Villa within the 2012 World Travel Awards.

Comments General Manager, Karl Lambour: We are extremely proud to have been nominated for our unique accommodation, The Owners Cottage, which forms part of the exclusive Grande Provence experience - The Restaurant, The Jonkershuis, The Gallery, The Shop and The Tasting Room as well as our fine cuisine and award-winning signature wines.

This year marks the 19th World Travel Awards, which acknowledges excellence within the global travel and tourism industry and is voted by numerous travel agents worldwide.

Read more:

'The Owner’s Cottage' in line for World Travel Award

Private Space Taxi Builders Pass Key Milestones for NASA

Two commercial spaceflight companies have checked off vital milestones on the path toward flights to the International Space Station for NASA, the space agency announced today (Aug. 23).

The Hawthorne, Calif.-based SpaceX has completed its Space Act Agreement under NASA's Commercial Orbital Transportation Services program, or COTS. The company is slated to launch the first of its 12 contracted robotic cargo flights to the space station from Florida's Cape Canaveral Air Force Station in October, officials said.

Meanwhile, theDream Chaser space planebeing developed by Sierra Nevada Space Systems in Colorado has reached its first milestone a program implementation plan review under NASA's recently announced Commercial Crew integrated Capability initiative. CCiCap is part of the agency's effort to spur the development of private American crew-carrying spaceships, to fill the void left by the space shuttle's retirement.

"We're working to open a new frontier for commercial opportunities in space and create job opportunities right here in Florida and across the United States," Bolden said from NASA's Kennedy Space Center. "And we're working to in-source the work that is currently being done elsewhere and bring it right back here to the U.S. where it belongs." [Top 10 Private Spaceships]

Would you take a ride on SpaceX's Dragon space capsule?

SpaceX has already flown to the space station once as part of its COTS partnership. The company's unmanned Dragon capsule docked to the orbiting lab during a historic demonstration mission in May, becoming the first private vehicle ever to do so.

The flight was designed to test whether Dragon and SpaceX's Falcon 9 rocket were ready to begin the 12 official resupply flights, for which SpaceX holds a NASA contract worth $1.6 billion.

NASA also signed a $1.9 billion deal with Virginia-based Orbital Sciences Corp. for eight robotic cargo flights with its Cygnus vessel. Orbital plans to launch its first test flight with Cygnus this winter, NASA officials said.

Earlier this month, NASA announced that Sierra Nevada will receive $212.5 million under CCiCap, the latest initiative of the agency's Commercial Crew Program. SpaceX will get $440 million to help upgrade Dragon to a crew-carrying craft, while Boeing was awarded $460 million for its CST-100 capsule.

The Commercial Crew Program also awarded funding to private spaceflight firms in each of the last two years, in rounds known as Commercial Crew Development 1 and 2. Sierra Nevada got funding during both CCDev-1 and CCDev-2 as well.

Here is the original post:

Private Space Taxi Builders Pass Key Milestones for NASA

Smooth sailing: Space launch system giving Marshall, Langley wind tunnels a workout

ScienceDaily (Aug. 23, 2012) Launching rockets is no easy or inexpensive task. Developers must consider the ground support infrastructure, fuel elements and flight hardware itself; not to mention the safety of everyone involved.

Since well before the inception of NASA, engineers used wind tunnels and scale models to test how vehicles would respond and interact with the atmosphere. At the Marshall Space Flight Center in Huntsville, Ala., and Langley Research Center in Hampton, Va., engineers are using wind tunnel testing to enhance the development of NASA's Space Launch System, a heavy-lift launch vehicle that will propel science and human exploration into deep space and launch NASA's Orion spacecraft to expand human presence beyond low Earth orbit.

Engineers at Marshall's Trisonic Wind Tunnel have spent the past four months putting early SLS scale models through more than 900 tests of various crew and cargo configurations.

"We need to evaluate all the possible conditions that the launch vehicle may encounter as it traverses the atmosphere," said John Blevins, SLS lead engineer for aerodynamics and acoustics. "We look at many different configurations and designs of the same rocket, discovering how it reacts under variations in flight conditions. It is a very busy and exciting time for us."

The Trisonic Wind Tunnel is testing the flight stability of SLS, providing the initial configuration testing and the basis to assess flight stability. Testing on a larger geometric scale at Langley's Unitary Plan Wind Tunnel and tests planned for Boeing's Polysonic Wind Tunnel in St. Louis will improve understanding of the vehicle's aerodynamics as the design matures. The Langley facility can accurately test limits of rocket designs, but only at speeds above Mach 1.5. The Boeing facility will be used for the lower Mach conditions on the larger model. At Marshall, tests are conducted to determine how the designs respond to roll, pitch and yaw at speeds from Mach 0.3 to Mach 5. The data from both tunnels will be merged to evaluate the design's performance, guidance and control.

"Once we analyze the data, we can determine the best configuration and refine our design of the vehicle," said SLS Chief Engineer Garry Lyles. "Any changes can be made safely, easily and inexpensively before the full-scale version is built. This helps ensure that SLS is an affordable and sustainable capability for human space exploration beyond low Earth orbit."

On a larger scale, engineers use wind tunnels to evaluate unsteady aerodynamic effects that can cause vehicle vibrations and resonance. The biggest SLS wind tunnel model test to date is scheduled for mid-September. Langley's Transonic Dynamics Tunnel will test the first large scale integrated model -- a 12-foot-long version of the heavy-lift rocket to evaluate these unsteady aerodynamic phenomena.

Each test moves the agency closer to giving the nation a launch capability to take humans farther than ever before. Designed to be flexible for launching spacecraft for crew and cargo missions, including NASA's Orion multipurpose vehicle, SLS will enable NASA to meet the president's goal of sending humans to an asteroid by 2025 and to Mars in the 2030s.

For more information about the Space Launch System, including the newest proposed rocket configurations, visit: http://www.nasa.gov/sls

Share this story on Facebook, Twitter, and Google:

See the original post:

Smooth sailing: Space launch system giving Marshall, Langley wind tunnels a workout

Is NASA focusing too much on Mars? (+video)

Even as the Curiosity Mars rover was still testing its equipment in preparation for its surface mission, NASA has unveiled plans for another unmanned mission to Mars. Is the agency playing favorites?

NASA unveiled plans this week for a brand-new mission to Mars in 2016, even as its newest rover was just settling in on the Red Planet. But space agency officials say it's not a case of Red Planet favoritism.

Subscribe Today to the Monitor

Click Here for your FREE 30 DAYS of The Christian Science Monitor Weekly Digital Edition

On Monday (Aug. 20), NASA announced that its next low-budget exploration effort will launch a lander called InSight to Mars in 2016 to investigate the Red Planet's interior. InSight's selection comes barely two weeks after the agency's $2.5 billion Curiosity rover touched down inside Mars' huge Gale Crater.

NASA's golf-cart-size Opportunity rover is still cruising around the Red Planet more than eight years after it landed with its twin, Spirit. And the space agency has two orbiters Mars Odyssey and the Mars Reconnaissance Orbiter actively observing the planet from above.

No other planet has received nearly this much attention in recent years. But NASA isn't too narrowly focused, officials said.

"We still have an extremely broad portfolio of missions, you know, heading out into the solar system now for instance, Juno on its way to Jupiter, Osiris-Rex being worked in preparation for its mission to an asteroid," John Grunsfeld, associate administrator for NASA's Science Mission Directorate, told reporters Monday. "And so I think we've shown very broad diversity in past selections."

Grunsfeld also cited the Dawn probe which has been studying the huge asteroid Vesta for the past year and is getting set to depart for the dwarf planet Ceres next month and New Horizons, which is speeding toward a flyby of Pluto in 2015. [Quiz: How Well Do You Know Mars?]

InSight short for Interior exploration using Seismic Investigations, Geodesy and Heat Transport will be NASA's 12th Discovery-class mission, and its cost is capped at $425 million in 2010 dollars (excluding the launch vehicle).

Continued here:

Is NASA focusing too much on Mars? (+video)